Neuro-Oncology News

Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center.

This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.”

Researchers at Johns Hopkins University are conducting the first clinical trials to evaluate the potential of a pinworm medication for the treatment of children and adults with newly diagnosed glioblastoma.

Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General Practitioner’s Oral Contraception Study.

CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology.

The FDA granted breakthrough therapy designation to burtomab for the treatment of pediatric patients with relapsed or refractory neuroblastoma who have central nervous system or leptomeningeal metastasis.

The FDA denied approval of Coherus BioSciences’ biologics license application for CHS-1701, a proposed biosimilar for pegfilgrastim.

President Donald J. Trump selected Norman E. “Ned” Sharpless, MD, to serve as director of NCI.

CHICAGO — Andrew B. Lassman, MD, discusses advances made within two major themes — precision medicine and immunotherapy — for the treatment of primary brain tumors at the ASCO Annual Meeting.

CHICAGO — Epacadostat in combination with nivolumab appeared safe and effective in patients with advanced melanoma and head and neck cancer, according to preliminary data from the ECHO-204 trial presented at the ASCO Annual Meeting.